GSE74071 DNA methylation in human pancreatic cancer vs. adjacent normal pancreatic tissue

Contributors : Po-Hsien Huang ; Yan-Shen ShanSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensHumanMethylation 450K microarrays were used to identify aberrant DNA methylation in pancreatic adenocarcinoma (n=14), juice-circulating cancer cells (n=4), cancer associated fibroblasts (n=3), against adjacent normal pancreatic tissues (n=7)Bisulphite converted DNA from the 28 samples were hybridised to the Illumina HumanMethylation450 Beadchip v1.2
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Methylation profiling by genome tiling array Homo sapiens Source Type: research

Related Links:

Objective: First, to assess the impact of the number of examined lymph nodes (ELNs) on staging and survival after distal pancreatectomy (DP) for pancreatic adenocarcinoma (PDAC). Second, to identify the minimum number of ELNs (MNELNs) ensuring an accurate detection of nodal involvement. Third, to reappraise the role of lymph node (LN) parameters, including N-status and lymph node ratio (LNR). Background: In contrast with pancreatoduodenectomy, information on LN staging and the MNELN required in DP is lacking. Methods: Patients undergoing DP for PDAC at 2 academic hospitals from 2000 through 2013 were retrospectivel...
Source: Annals of Surgery - Category: Surgery Tags: ORIGINAL ARTICLES Source Type: research
AbstractInterferon-stimulated gene 15 (ISG15) is a 15  kDa protein induced by type I interferons (IFN-α and IFN-β) and is a member of the ubiquitin-like superfamily of proteins. The ISG15 pathway is highly expressed in various malignancies, including pancreatic ductal adenocarcinoma (PDAC), suggesting a potential role of the ISG15 pathway (free ISG1 5 and ISG15 conjugates) in pancreatic carcinogenesis. However, very little is known about how the ISG15 pathway may contribute to pancreatic tumorigenesis. In the current study, we demonstrate that ISG15 pathway knockdown reverses the KRAS-associated phenotypes ...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
ysal-Onganer Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer, proving difficult to manage clinically. Wnt-11, a developmentally regulated gene producing a secreted protein, has been associated with various carcinomas but has not previously been studied in PDAC. The present study aimed to elucidate these aspects first in vitro and then in a clinical setting in vivo. Molecular analyses of Wnt-11 expression as well as other biomarkers involved qRT-PCR, RNA-seq and siRNA. Proliferation was measured by MTT; invasiveness was quantified by Boyden chamber (Matrigel) assay. Wnt-11 mRNA was presen...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
Pancreatic adenocarcinoma (PDAC) is the most common type of pancreatic cancer (PC) [1 –3]. PDAC incidence is rising; it is expected to become the second cause of cancer-related death by 2030 and has a very poor prognosis[4]. More than 80% of patients have an advanced disease at diagnosis, and the 5-year overall survival rate is approximately 7% [5]. Poor survival is attributed to h igh aggressiveness, intrinsic chemotherapeutics resistance and lack of effectively targetable oncogenic drivers. Systemic chemotherapy is the mainstay of locally advanced (LAPC) and metastatic (MPC) patients treatment and single-agent gemc...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Tumour Review Source Type: research
This study was performed to investigate the potential role of LINC01638 in pancreatic ductal adenocarcinoma (PDAC). The expression of LINC01638 was determined via reverse transcription‑quantitative polymerase chain reaction analysis, whereas the levels of transforming growth factor‑β1 (TGF‑β1) in plasma were measured via ELISA. Receiver operating characteristic curve analysis was conducted to determine the diagnostic value of LINC01638. Additionally, the migratory and invasive abilities of cells were evaluated via Transwell migration and invasion assays. In the present study, LINC01638 was significantly upr...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Conditions:   Pancreatic Adenocarcinoma;   Pancreatic Cancer Intervention:   Biological: Autologous DC vaccine Sponsors:   Baylor College of Medicine;   Cancer Cures for Kids Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Authors: Visochek L, Atias D, Spektor I, Castiel A, Golan T, Cohen-Armon M Abstract Recent reports demonstrate an exclusive eradication of a variety of human cancer cells by the modified phenanthridine PJ34. Their eradication during mitosis is attributed to PJ34 preventing NuMA clustering in the mitotic spindle poles of human malignant cells, which is crucial for their normal mitosis. Here, the effect of PJ34 is tested in cell cultures and xenografts of human pancreas ductal adenocarcinoma. Evidence is presented for a substantial reduction (80-90%) of PANC1 cancer cells in xenografts, measured 30 days after the tre...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Sanford NN, Aguilera TA, Folkert MR, Ahn C, Mahal BA, Zeh H, Beg MS, Mansour J, Sher DJ Abstract BACKGROUND: Adjuvant therapy for resected pancreatic adenocarcinoma was given a category 1 NCCN recommendation in 2000, yet many patients do not receive chemotherapy after definitive surgery. Whether sociodemographic disparities exist for receipt of adjuvant chemotherapy is poorly understood. METHODS: The National Cancer Database was used to identify patients diagnosed with nonmetastatic pancreatic adenocarcinoma who underwent definitive surgery from 2004 through 2015. Multivariable logistic regression defi...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
This study aimed to clarify the clinical significance of the reticular pattern in pancreatic head cancer.MethodsA total number of 91 patients with pancreatic head cancer, who underwent upfront pancreaticoduodenectomy between 2004 and 2017, were included. Patients without reticular pattern (Non ‐group, 39); with reticular pattern around SMA (Ret‐group, 39); and with soft tissue contact (Soft‐group, 13) were compared.ResultsMedian overall survival (OS) of patients in the Ret ‐group was significantly worse than that in the Non‐group (21.3 vs 57.0 months;P
Source: Journal of Hepato-Biliary-Pancreatic Sciences - Category: Gastroenterology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Nature Reviews Clinical Oncology, Published online: 08 November 2019; doi:10.1038/s41571-019-0281-6Virtually all patients with resectable pancreatic ductal adenocarcinoma (PDAC) will have disease progression, which is generally associated with dismal outcomes. However, novel targeted therapies and immunotherapies, selected based on the genomic and/or clinical features of patients’ tumours are beginning to improve the outcomes in subsets of patients. In this Review, the authors describe progress in novel therapies for patients with PDAC.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Genetics | Pancreas | Pancreatic Cancer